These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 22580227)

  • 21. Photo-triggered fluorescent theranostic prodrugs as DNA alkylating agents for mechlorethamine release and spatiotemporal monitoring.
    Cao Y; Pan R; Xuan W; Wei Y; Liu K; Zhou J; Wang W
    Org Biomol Chem; 2015 Jun; 13(24):6742-8. PubMed ID: 25997534
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A new cyclopamine glucuronide prodrug with improved kinetics of drug release.
    Renoux B; Legigan T; Bensalma S; Chadéneau C; Muller JM; Papot S
    Org Biomol Chem; 2011 Dec; 9(24):8459-64. PubMed ID: 22042246
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The azaquinone-methide elimination: comparison study of 1,6- and 1,4-eliminations under physiological conditions.
    Erez R; Shabat D
    Org Biomol Chem; 2008 Aug; 6(15):2669-72. PubMed ID: 18633521
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Self-assembling nanomicelles of a novel camptothecin prodrug engineered with a redox-responsive release mechanism.
    Li XQ; Wen HY; Dong HQ; Xue WM; Pauletti GM; Cai XJ; Xia WJ; Shi D; Li YY
    Chem Commun (Camb); 2011 Aug; 47(30):8647-9. PubMed ID: 21725532
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A DT-diaphorase responsive theranostic prodrug for diagnosis, drug release monitoring and therapy.
    Liu P; Xu J; Yan D; Zhang P; Zeng F; Li B; Wu S
    Chem Commun (Camb); 2015 Jun; 51(46):9567-70. PubMed ID: 25971544
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rapidly cell-penetrating and reductive milieu-responsive nanoaggregates assembled from an amphiphilic folate-camptothecin prodrug for enhanced drug delivery and controlled release.
    Xu Z; Hou M; Shi X; Gao YE; Xue P; Liu S; Kang Y
    Biomater Sci; 2017 Feb; 5(3):444-454. PubMed ID: 28058423
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bioactivation of carbamate-based 20(S)-camptothecin prodrugs.
    Pessah N; Reznik M; Shamis M; Yantiri F; Xin H; Bowdish K; Shomron N; Ast G; Shabat D
    Bioorg Med Chem; 2004 Apr; 12(8):1859-66. PubMed ID: 15051055
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-time monitoring of drug release.
    Weinstain R; Segal E; Satchi-Fainaro R; Shabat D
    Chem Commun (Camb); 2010 Jan; 46(4):553-5. PubMed ID: 20062859
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A prodrug nanoassembly entrapping drugs as a tumor-targeted delivery system.
    Yuan Z; Yi X; Zhang J; Cheng S; Zhuo R; Li F
    Chem Commun (Camb); 2013 Jan; 49(8):801-3. PubMed ID: 23235958
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Benzyl ether-linked glucuronide derivative of 10-hydroxycamptothecin designed for selective camptothecin-based anticancer therapy.
    Leu YL; Chen CS; Wu YJ; Chern JW
    J Med Chem; 2008 Mar; 51(6):1740-6. PubMed ID: 18318465
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bioactivation of self-immolative dendritic prodrugs by catalytic antibody 38C2.
    Shamis M; Lode HN; Shabat D
    J Am Chem Soc; 2004 Feb; 126(6):1726-31. PubMed ID: 14871103
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prodrug-based nanoparticulate drug delivery strategies for cancer therapy.
    Luo C; Sun J; Sun B; He Z
    Trends Pharmacol Sci; 2014 Nov; 35(11):556-66. PubMed ID: 25441774
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted theranostic platinum(IV) prodrug with a built-in aggregation-induced emission light-up apoptosis sensor for noninvasive early evaluation of its therapeutic responses in situ.
    Yuan Y; Kwok RT; Tang BZ; Liu B
    J Am Chem Soc; 2014 Feb; 136(6):2546-54. PubMed ID: 24437551
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An activatable theranostic for targeted cancer therapy and imaging.
    Bhuniya S; Maiti S; Kim EJ; Lee H; Sessler JL; Hong KS; Kim JS
    Angew Chem Int Ed Engl; 2014 Apr; 53(17):4469-74. PubMed ID: 24644015
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What should be considered on design of a colon-specific prodrug?
    Jung Y; Kim YM
    Expert Opin Drug Deliv; 2010 Feb; 7(2):245-58. PubMed ID: 20095945
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Self-immolative nitrogen mustard prodrugs for suicide gene therapy.
    Niculescu-Duvaz D; Niculescu-Duvaz I; Friedlos F; Martin J; Spooner R; Davies L; Marais R; Springer CJ
    J Med Chem; 1998 Dec; 41(26):5297-309. PubMed ID: 9857097
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor-targeted bioconjugate based delivery of camptothecin: design, synthesis and in vitro evaluation.
    Paranjpe PV; Chen Y; Kholodovych V; Welsh W; Stein S; Sinko PJ
    J Control Release; 2004 Nov; 100(2):275-92. PubMed ID: 15544875
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Guided molecular missiles for tumor-targeting chemotherapy--case studies using the second-generation taxoids as warheads.
    Ojima I
    Acc Chem Res; 2008 Jan; 41(1):108-19. PubMed ID: 17663526
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug delivery by an enzyme-mediated cyclization of a lipid prodrug with unique bilayer-formation properties.
    Linderoth L; Peters GH; Madsen R; Andresen TL
    Angew Chem Int Ed Engl; 2009; 48(10):1823-6. PubMed ID: 19173369
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modulating paclitaxel bioavailability for targeting prostate cancer.
    Kumar SK; Williams SA; Isaacs JT; Denmeade SR; Khan SR
    Bioorg Med Chem; 2007 Jul; 15(14):4973-84. PubMed ID: 17502149
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.